S
Singular Genomics Systems
Biotech & Life Sciences · San Diego, United States · Founded 2016 · IPO 2021
Accelerating genomics for the advancement of science and medicine MoreLess
Singular Genomics, founded in 2016 by Drew, is a biotechnology company based in San Diego, California. The company focuses on advancing genomics, which is the study of an organism's complete set of DNA, including all of its genes. Singular Genomics aims to accelerate scientific and medical research by providing innovative tools and technologies for genomic sequencing.
The company serves a variety of clients, including academic researchers, pharmaceutical companies, and clinical laboratories. These clients use Singular Genomics' products to conduct multiomic research, which involves studying various types of biological data, such as DNA, RNA, and proteins, to understand complex biological systems and diseases.
Singular Genomics operates in the genomics market, which is a rapidly growing sector within the broader biotechnology industry. The company's flagship product is the G4 sequencing platform, an ultra-high throughput, high-resolution spatial sequencing system. This platform allows researchers to process multiple samples simultaneously, making it faster and more efficient to conduct large-scale genomic studies.
The business model of Singular Genomics revolves around selling its sequencing platforms and related consumables, such as flow cells, which are essential components used in the sequencing process. The company generates revenue by selling these products to its clients, who rely on them for their research and clinical applications.
In summary, Singular Genomics is a forward-thinking biotech company dedicated to advancing genomics through innovative sequencing technologies. By providing high-performance tools for genomic research, the company supports the scientific and medical communities in their efforts to understand and treat complex diseases.
Keywords: genomics, sequencing, biotechnology, multiomic research, DNA, RNA, proteins, G4 platform, academic researchers, pharmaceutical companies.
Talent graph
Singular Genomics Systems's talent
Source: Dealroom Talent Intelligence.
Investors
10 investors on Singular Genomics Systems's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Global footprint
Where Singular Genomics Systems has talent and traffic
team presence
across markets
Patent intelligence
$27M patent portfolio · 111 active families
Where Singular Genomics Systems concentrates vs peers
Each axis is a top-10 topic across Singular Genomics Systems and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Singular Genomics Systems
An AI-synthesized read of the highest-engagement posts about Singular Genomics Systems on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Singular Genomics Systems on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.



